CoChat

Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials—GPPAD‐02 study design and first results

Open access
Winkler, Christiane, Haupt, Florian, Heigermoser, Martin, Zapardiel‐Gonzalo, Jose, Ohli, Jasmin, Faure, Theresa, Kalideri, Evdokia, Hommel, Angela, Delivani, Petrina, Berner, Reinhard, Kordonouri, Olga, Roloff, Frank, von dem Berge, Thekla, Lange, Karin, Oltarzewski, Mariusz, Glab, Ryszard, Szypowska, Agnieszka, Snape, Matthew D., Vatish, Manu, Todd, John A., Larsson, Helena E., Ramelius, Anita, Kördel, Jeanette Å., Casteels, Kristina, Paulus, Jasmin, Ziegler, Anette G., Bonifacio, Ezio, the GPPAD Study Group · 2019 · Pediatric Diabetes
Cited by 61

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Primary prevention of type 1 diabetes (T1D) requires intervention in genetically at-risk infants. The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) has established a screening program, GPPAD-02, that identifies infants with a genetic high risk of T1D, enrolls these into primary prevention trials, and follows the children for beta-cell autoantibodies and diabetes. Genetic testing is offered either at delivery, together with the regular newborn testing, or at a newborn health care visits before the age of 5 months in regions of Germany (Bavaria, Saxony, Lower Saxony), UK (Oxford), Poland (Warsaw), Belgium (Leuven), and Sweden (Region Skåne). Seven clinical centers will screen around 330 000 infants. Using a genetic score based on 46 T1D susceptibility single-nucleotide polymorphisms (SNPs) or three SNPS and a first-degree family history for T1D, infants with a high (>10%) genetic risk for developing multiple beta-cell autoantibodies by the age of 6 years are identified. Screening from October 2017 to December 2018 was performed in 50 669 infants. The prevalence of high genetic risk for T1D in these infants was 1.1%. Infants with high genetic risk for T1D are followed up and offered to participate in a randomized controlled trial aiming to prevent beta-cell autoimmunity and T1D by tolerance induction with oral insulin. The GPPAD-02 study provides a unique path to primary prevention of beta-cell autoimmunity in the general population. The eventual benefit to the community, if successful, will be a reduction in the number of children developing beta-cell autoimmunity and T1D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/pedi.12870

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Winkler, C., Haupt, F., Heigermoser, M., Zapardiel‐Gonzalo, J., Ohli, J., Faure, T., Kalideri, E., Hommel, A., Delivani, P., Berner, R., Kordonouri, O., Roloff, F., von dem Berge, T., Lange, K., Oltarzewski, M., Glab, R., Szypowska, A., Snape, M. D., Vatish, M., Todd, J. A., Larsson, H. E., Ramelius, A., Kördel, J. Å., Casteels, K., Paulus, J., Ziegler, A. G., Bonifacio, E., & the GPPAD Study Group
Venue
Pediatric Diabetes
Publisher
Wiley
Published
2019-06-13
Volume
20
Issue
6
Pages
720-727
ISSN
  • 1399-543X (ISSN-L)
  • 1399-5448
OpenAlex
W2949088599
Cited by
61
References
6
FWCI
3.25
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.